European Archives - Page 5 of 1349 - European Medical Journal

Handshake

Lilly and NVIDIA: a $1bn leap for drug discovery

Eli Lilly and NVIDIA have unveiled a first-of-its-kind AI co-innovation lab, aiming to solving the most complex bottlenecks in pharma.

D-dimer

Simplified D-Dimer Strategy Safely Rules Out Pulmonary Embolism

A 1000 ng/mL D-dimer threshold safely rules out pulmonary embolism in low-likelihood patients, reducing unnecessary chest imaging in emergency care.

lung cancer

Machine Learning Supports Radiology Lung Cancer Screening

A machine learning lung cancer risk model showed improved accuracy over traditional methods, with potential to enhance patient selection for radiology based lung cancer screening.

lipoprotein(a)

Lipoprotein(a) and Thirty-Year Risk of Cardiovascular Disease in Women

Very high lipoprotein(a) predicts decades of cardiovascular risk, guiding screening, personalised prevention, and earlier clinical intervention for women.

lung cancer

Immunotherapy Benefits Patients with Stage III Lung Cancer

Perioperative nivolumab significantly improved survival and pathological response in stage III non-small-cell lung cancer, challenging the traditionally poor prognosis associated with N2 nodal disease.

mazdutide

Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial

Mazdutide, a dual glucagon and GLP-1 agonist, delivers greater HbA1c and weight reductions than dulaglutide in people with type 2 diabetes.

Anti-Inflammatory Treatment Reduces Depressive Symptoms

Across these trials, anti-inflammatory treatment significantly reduced anhedonia, defined as reduced capacity to experience pleasure, with a moderate effect size.

Osteoarthritis and Chronic Pain in a Shifting World

Chronic pain, particularly in the context of rheumatic diseases, represents one of the most pervasive global health challenges, affecting…

desktop showing data

Pharma to FDA: Upgrade cell and gene data sharing

The pharmaceutical industry is calling on the FDA to modernise how it tracks the long-term safety and efficacy of cell and gene therapies.

Why Rheumatoid Arthritis Remission Rates Remain Stagnant

A national cohort study shows rheumatoid arthritis remission rates in England and Wales have plateaued since 2018, with wide regional variation and delays before specialist referral limiting progress